Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers

Head and Neck

Volumn 31, Issue 4, 2009, Pages 493-502

  Watkins, John M ^a   Shirai, Keisuke S ^b   Wahlquist, Amy E ^b   Stuart, Robert K ^b   Chaudhary, Uzair B ^b   Garrett Mayer, Elizabeth ^b   Day, Terry A ^a   Gillespie, M Boyd ^a   Sharma, Anand K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chemoradiotherapy; Head and neck neoplasms; Reirradiation; Salvage therapy; Squamous cell carcinoma

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; FLUOROURACIL; HYDROXYUREA; PACLITAXEL;

ADULT; AGED; ARTICLE; BLEEDING; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; ESOPHAGUS STRICTURE; FACIAL NERVE PARALYSIS; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARYNGITIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECURRENT CANCER; RETROSPECTIVE STUDY; TRACHEOMALACIA; TREATMENT FAILURE; TRISMUS; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIATION INJURIES; RETREATMENT; SURVIVAL RATE;

EID: 65649114772     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20986     Document Type: Article

References (23)

1. ForastiereA,KochW,TrottiA,SidranskyD.Headandneckcancer.NEnglJMed2001;345: 1890-1900.(Pubitemid33716564)
2. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.
3. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952.
4. Agra IMG, Carvalho AL, Ulbrich FS, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck 2006;28:107-113.
5. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110(Suppl 93):1-18.
6. Lee SC, Shores CG, Weissler MC. Salvage surgery after failed primary concomitant chemoradiation. Curr Opin Otolaryngol Head Neck Surg 2008;16:135-140.
7. HarafDJ,WeichselbaumRR,VokesEE.Re- irradiationwithconcomitantchemotherapyofunresectablerecurrentheadandneckcancer: apotentiallycurabledisease.AnnOncol1996;7:913-918.(Pubitemid26426265)
8. Spencer SA, Wheeler RH, Peters GE, et al. Concomitant chemotherapy and re-irradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol 1999;22:1-5.
9. Kramer NM, Horwitz EM, Cheng J, et al. Toxicity and outcome analysis of patient with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective I and II studies. Head Neck 2005;27:406-414.
10. StevensKR,BritschA,MossWT.High- dosereirradiationofheadandneckcancerwithcurativeintent. IntJRadiatOncolBiolPhys1994;29:687-698.(Pubitemid24241307)
11. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:731-740.
12. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006;64:382-391.
13. De Crevoisier R, Bourhis J, Domenge C, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998;16:3556-3562.
14. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 96-10, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008;30:281-288.
15. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of the Radiation Therapy Oncology Group protocol 9911. J Clin Oncol 2007;25:4800-4805.
16. Bourhis J, De Raucourt D, Castaing M, et al. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a randomized trial from the GORTEC and GETTEC. Radiother Oncol 2006;81 (Suppl 1):S147.
17. Kasperts N, Slotman BJ, Leemans CR, et al. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer 2006;106:1536-1547.
18. Horwitz EM, Harris J, Langer CJ, et al. Phase II study of paclitaxel and cisplatin in combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell carcinoma of the head and neck: results of RTOG 99-11. Int J Radiat Oncol Biol Phys 2005(Suppl 2):63:S72-S73.
19. Milano MT, Vokes EE, Salama JK, et al. Twice-daily reirradiation for recurrent and second primary head-and- neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys 2005;61:1096-1106.
20. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel, cisplatin, granulocyte colony-stimulating factor versus low-dose paclitaxel and cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001;19:1088-1095.
21. Gibson MK, Li Y, Hussain MH, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
22. Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - results of a randomized phase III (EXTREME) study. J Clin Oncol 2008;25(Suppl 1):A6091.
23. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004;101:2222-2229.